Cwm LLC cut its position in shares of Natus Medical Inc (NASDAQ:BABY) by 4.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 49,542 shares of the medical equipment provider’s stock after selling 2,212 shares during the quarter. Cwm LLC owned about 0.16% of Natus Medical worth $1,893,000 at the end of the most recent quarter.
A number of other large investors have also recently made changes to their positions in the business. Benjamin F. Edwards & Company Inc. grew its stake in shares of Natus Medical by 2,085.6% in the third quarter. Benjamin F. Edwards & Company Inc. now owns 2,732 shares of the medical equipment provider’s stock valued at $102,000 after buying an additional 2,607 shares in the last quarter. Riverhead Capital Management LLC grew its stake in shares of Natus Medical by 90.9% in the second quarter. Riverhead Capital Management LLC now owns 2,864 shares of the medical equipment provider’s stock valued at $107,000 after buying an additional 1,364 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of Natus Medical in the third quarter valued at about $138,000. Victory Capital Management Inc. grew its stake in shares of Natus Medical by 17.6% in the second quarter. Victory Capital Management Inc. now owns 3,744 shares of the medical equipment provider’s stock valued at $140,000 after buying an additional 560 shares in the last quarter. Finally, Flinton Capital Management LLC grew its stake in shares of Natus Medical by 82.0% in the second quarter. Flinton Capital Management LLC now owns 3,774 shares of the medical equipment provider’s stock valued at $141,000 after buying an additional 1,700 shares in the last quarter. Institutional investors own 99.87% of the company’s stock.
In other Natus Medical news, Director William M. Moore sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $41.01, for a total transaction of $205,050.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Dong Chune Christopher Chung sold 12,642 shares of the firm’s stock in a transaction that occurred on Monday, November 6th. The shares were sold at an average price of $42.91, for a total value of $542,468.22. Following the sale, the vice president now owns 141,414 shares of the company’s stock, valued at approximately $6,068,074.74. The disclosure for this sale can be found here. 5.50% of the stock is owned by company insiders.
Shares of Natus Medical Inc (NASDAQ BABY) opened at $28.55 on Friday. Natus Medical Inc has a 12 month low of $28.05 and a 12 month high of $43.60. The company has a quick ratio of 3.36, a current ratio of 4.21 and a debt-to-equity ratio of 0.36. The stock has a market capitalization of $876.99, a PE ratio of -317.19 and a beta of 0.84.
Natus Medical (NASDAQ:BABY) last issued its quarterly earnings data on Wednesday, October 25th. The medical equipment provider reported $0.40 earnings per share for the quarter, beating analysts’ consensus estimates of $0.38 by $0.02. Natus Medical had a positive return on equity of 12.06% and a negative net margin of 0.62%. The firm had revenue of $122.60 million during the quarter, compared to analyst estimates of $122.41 million. During the same quarter last year, the firm earned $0.39 EPS. Natus Medical’s quarterly revenue was up 34.9% on a year-over-year basis. analysts expect that Natus Medical Inc will post 1.64 EPS for the current year.
A number of research firms have recently issued reports on BABY. Benchmark reiterated a “buy” rating and issued a $49.00 target price (down previously from $55.00) on shares of Natus Medical in a research note on Tuesday. Zacks Investment Research lowered Natus Medical from a “hold” rating to a “strong sell” rating in a research note on Thursday, January 11th. William Blair lowered Natus Medical from an “outperform” rating to a “market perform” rating in a research note on Monday, January 8th. Finally, BidaskClub lowered Natus Medical from a “sell” rating to a “strong sell” rating in a research note on Saturday, January 6th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and one has issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $47.00.
WARNING: This piece of content was reported by Transcript Daily and is the property of of Transcript Daily. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://transcriptdaily.com/2018/01/19/natus-medical-inc-baby-shares-sold-by-cwm-llc.html.
Natus Medical Company Profile
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.